ALGN

Business profile & competitive position

Align Technology, Inc. operates in the Healthcare sector under the Medical - Devices industry. Its core products are the Invisalign system of clear aligners, Vivera retainers, iTero intraoral scanners, and exocad CAD/CAM software, all tied together by the Align Digital Platform. That platform is positioned as an end-to-end digital workflow connecting orthodontists, general dental practitioners, dental laboratories, and patients. According to the company’s most recent 10-K, the Clear Aligner segment generated roughly 80% of 2025 worldwide net revenues, while Systems and Services contributed the remaining 20%.

The financial signatures of the business are a 10.0% net margin and a 10.1% return on equity. Those are positive but not especially wide for a medical-device category that is often associated with premium pricing and recurring consumables. The 10-K notes that globally more than 95% of Invisalign System prescription orders are submitted via digital scan, which points to a high degree of workflow integration and lower reliance on physical impressions. That operational adoption supports an ecosystem argument, but the margin and ROE figures imply that competitive pressure and operating leverage remain material considerations rather than evidence of an unassailable moat.

Financial posture

As of the snapshot, Align carries an $11.4 billion market capitalization, trades at a trailing P/E of 27.5, and posts a 10.0% net margin alongside a 10.1% ROE. Its beta is 1.64, meaning the stock has historically shown materially higher volatility than the overall market. The current price is $158.635, with a 50-day exponential moving average of $168.14 and an RSI of 41.8.

Together these figures frame a growth-oriented valuation on a stock that has recently weakened: the price sits below its 50-day EMA and the RSI is in neutral-to-soft territory. A P/E of 27.5 prices in meaningful future earnings expansion, while the 10.0% net margin and 10.1% ROE suggest the company is profitable but not at the upper tier of healthcare margins. The elevated beta warns that reaction to clinical data, competitor launches, or macro headlines can be amplified relative to the broader sector.

Strategic priorities & outlook

Align’s most recent 10-K outlines four near-term priorities. First, it wants clear aligners—specifically the Invisalign System—to become the principal solution for malocclusion globally among orthodontists, general practitioners, and patients. Second, it aims to establish iTero intraoral scanners as the preferred technology for digital dental scans. Third, it is pushing exocad CAD/CAM software to become the dental restorative solution of choice for dental labs. Fourth, it is focused on growing share of orthodontic case starts versus traditional wires and brackets, especially among teens, while also expanding digital orthodontics among adults.

Operationally, the company reports that more than 95% of Invisalign System prescriptions are submitted digitally, reducing turnaround time and the carbon footprint associated with PVS impressions. In January 2024, Align acquired Cubicure to scale direct 3D printing capabilities, and it has begun limited manufacturing of certain appliances with plans to pilot additional devices, including retainers and selected pre-fabricated attachments, in limited releases during 2026. Those initiatives align with the stated goal of tightening the digital workflow from scan to finished appliance.

Macro & geopolitical exposure

As a Healthcare / Medical - Devices company selling capital equipment and consumables into dental markets around the world, Align is exposed to several macro and geopolitical channels. Regulatory clearance and quality compliance are central; aligners, scanners, and software must meet FDA or equivalent standards in each country where they are sold, and changes in data-privacy or medical-device regulation can affect speed to market and operating costs.

International revenue introduces foreign-exchange exposure, while tariffs or trade restrictions on scanners, resins, polymer materials, and 3D-printing components can influence manufacturing costs. Supply-chain reliability for specialized optical components, polymers, and 3D-printing inputs matters because any constraint can ripple through scanner production and aligner fabrication. Reimbursement and consumer-discretionary dynamics are also relevant: orthodontic treatment is partially out-of-pocket in many markets, so household spending capacity and dental-insurance coverage can affect case-start volumes. Finally, currency weakness in emerging markets or tighter credit conditions for dental practices can dampen demand for both aligners and capital equipment.

Recent developments

The most recent headlines have centered on governance, ownership flows, and post-earnings price action.

• August 31, 2026: Align announced that Quentin Blackford will join its Board of Directors (businesswire.com).
• August 31, 2026: The Canada Pension Plan Investment Board disclosed an acquisition of 26,510 shares of Align Technology, Inc. (defenseworld.net).
• August 28, 2026: Zacks examined why Align Technology (ALGN) had fallen 8.4% since its last earnings report (zacks.com).
• August 17, 2026: GuruFocus noted that Align Technology stock was down 5.6% and highlighted a GF Score of 89 out of 100 (gurufocus.com).

Board additions and institutional accumulation are governance and capital-flow events rather than direct operational signals. The August 28 and August 17 articles underscore that the stock has been under pressure since reporting results, even as an external score rated the company relatively highly. These developments are consistent with the gap between solid fundamental metrics and short-term sentiment that can appear in volatile medtech names.

Earnings behavior & post-earnings drift

Over the last eight reported quarters Align has beaten earnings estimates seven times, for an 88% beat rate, with an average earnings surprise of 4.7%. Over those same quarters the average five-day price move following the report was 5.26%, classified as an upward drift. The headline numbers therefore suggest a stock that usually beats and that has tended, on average, to drift higher after reporting.

The recent quarter-by-quarter record, however, reveals a more complicated picture. The February 4, 2026 report delivered actual EPS of $3.29 versus an estimate of $2.99, a 10% surprise, and the stock jumped 8.88% the next day and 22.45% over the following five days. But that strong move pulls the average up. In the October 29, 2025 quarter, actual EPS of $2.61 beat the $2.40 estimate by 8.8%, yet the five-day move was a much smaller 4.02%. More telling, the April 29, 2026 quarter showed a 12.2% beat ($2.58 vs. $2.30) and the stock still fell 1.34% the next day and 2.5% over five days. The July 29, 2026 quarter was even more compressed: actual EPS of $2.64 beat the $2.62 estimate by only 0.8%, and the stock dropped 3.7% the next day and 2.92% over the following five sessions.

The takeaway is that beats have been frequent, but not a reliable signal for continued price appreciation. The unofficial consensus for the next report, scheduled on October 28, 2026, after the close, stands at $2.78. Traders who treat “beat equals pop and hold” as a rule may be surprised by the variability that has shown up in Align’s recent post-earnings price action.

For a deeper dive into the institutional consensus, forward estimates, and aggregate rating history behind these numbers, readers should review the full institutional verdict available on the platform.